E W St Clair

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. pmc Rituximab Therapy for Primary Sjögren's Syndrome: An Open-Label Clinical Trial and Mechanistic Analysis
    E William St Clair
    Duke University Medical Center, Durham, North Carolina
    Arthritis Rheum 65:1097-106. 2013
  2. pmc Serum, urinary, and salivary nitric oxide in rheumatoid arthritis: complexities of interpreting nitric oxide measures
    J Brice Weinberg
    Veterans Affairs Medical Center, 508 Fulton Street, Durham, NC 27705, USA
    Arthritis Res Ther 8:R140. 2006
  3. pmc The calm after the cytokine storm: lessons from the TGN1412 trial
    E William St Clair
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Clin Invest 118:1344-7. 2008
  4. pmc Infliximab treatment for rheumatic disease: clinical and radiological efficacy
    E W St Clair
    Department of Medicine, Division of Rheumatology, Duke University Medical Center, Durham, NC, USA
    Ann Rheum Dis 61:ii67-9. 2002
  5. ncbi request reprint The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial
    E William St Clair
    Duke University Medical Center, Durham, NC 27710, USA
    Arthritis Rheum 46:1451-9. 2002
  6. ncbi request reprint Treatment of rheumatoid arthritis with a DR4/1 peptide
    E W St Clair
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Rheumatol 27:1855-63. 2000
  7. ncbi request reprint A cross sectional analysis of 5 different markers of collagen degradation in rheumatoid arthritis
    E W St Clair
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Rheumatol 25:1472-9. 1998
  8. ncbi request reprint The effects of intravenous doxycycline therapy for rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial
    E W St Clair
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Arthritis Rheum 44:1043-7. 2001
  9. doi request reprint B cell-directed therapies for autoimmune disease and correlates of disease response and relapse
    Marc C Levesque
    Department of Medicine, Division of Rheumatology and Immunology, Duke University Medical Center, Durham, NC 27710, USA
    J Allergy Clin Immunol 121:13-21; quiz 22-3. 2008
  10. ncbi request reprint Tides of inflammation: impact of biologics
    E William St Clair
    J Rheumatol Suppl 65:22-6. 2002

Research Grants

  1. Abatacept Vs TNF Blockade in Early Rheumatoid Arthritis
    EUGENE ST CLAIR; Fiscal Year: 2007
  2. NOVEL THERAPEUTIC TARGETS IN RHEUMATOID ARTHRITIS
    EUGENE ST CLAIR; Fiscal Year: 2003
  3. Clinical Research Component
    EUGENE ST CLAIR; Fiscal Year: 2003
  4. Modulation of B Cell Responses in Autoimmunity
    EUGENE ST CLAIR; Fiscal Year: 2007
  5. ACR Basic Research Conference
    EUGENE ST CLAIR; Fiscal Year: 2007

Collaborators

Detail Information

Publications47

  1. pmc Rituximab Therapy for Primary Sjögren's Syndrome: An Open-Label Clinical Trial and Mechanistic Analysis
    E William St Clair
    Duke University Medical Center, Durham, North Carolina
    Arthritis Rheum 65:1097-106. 2013
    ..To study the safety and clinical efficacy of rituximab therapy for primary Sjögren's syndrome, as well as to investigate its mechanisms...
  2. pmc Serum, urinary, and salivary nitric oxide in rheumatoid arthritis: complexities of interpreting nitric oxide measures
    J Brice Weinberg
    Veterans Affairs Medical Center, 508 Fulton Street, Durham, NC 27705, USA
    Arthritis Res Ther 8:R140. 2006
    ..Despite interest in the use of NO as a marker of disease activity, alterations in renal NOx clearance and fractional excretion in RA make it difficult to assess in vivo NO production even with strict dietary restriction of NOx intake...
  3. pmc The calm after the cytokine storm: lessons from the TGN1412 trial
    E William St Clair
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Clin Invest 118:1344-7. 2008
    ....
  4. pmc Infliximab treatment for rheumatic disease: clinical and radiological efficacy
    E W St Clair
    Department of Medicine, Division of Rheumatology, Duke University Medical Center, Durham, NC, USA
    Ann Rheum Dis 61:ii67-9. 2002
    ..Recently, controlled studies have shown treatment with infliximab can benefit patients with active spondyloarthropathy. TNFalpha has fast become an important therapeutic target in rheumatology...
  5. ncbi request reprint The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial
    E William St Clair
    Duke University Medical Center, Durham, NC 27710, USA
    Arthritis Rheum 46:1451-9. 2002
    ..To investigate the relationship between serum concentrations of infliximab, a monoclonal anti-tumor necrosis factor alpha antibody, and clinical improvement from infliximab therapy for rheumatoid arthritis (RA)...
  6. ncbi request reprint Treatment of rheumatoid arthritis with a DR4/1 peptide
    E W St Clair
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Rheumatol 27:1855-63. 2000
    ..The primary outcomes were the occurrence of adverse effects and changes in measures of immune function. Clinical efficacy was assessed using the American College of Rheumatology 20% criteria for clinical improvement...
  7. ncbi request reprint A cross sectional analysis of 5 different markers of collagen degradation in rheumatoid arthritis
    E W St Clair
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Rheumatol 25:1472-9. 1998
    ..To compare 5 different assays measuring collagen degradation in rheumatoid arthritis (RA)...
  8. ncbi request reprint The effects of intravenous doxycycline therapy for rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial
    E W St Clair
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Arthritis Rheum 44:1043-7. 2001
    ..CONCLUSION: Although IV doxycycline therapy was generally well-tolerated by patients in this trial, it did not show any evidence of reducing disease activity or collagen crosslink production...
  9. doi request reprint B cell-directed therapies for autoimmune disease and correlates of disease response and relapse
    Marc C Levesque
    Department of Medicine, Division of Rheumatology and Immunology, Duke University Medical Center, Durham, NC 27710, USA
    J Allergy Clin Immunol 121:13-21; quiz 22-3. 2008
    ..Moreover, pathologic B-cell responses may be favorably influenced by other targeted approaches such as those using anti-B-cell activating factor belonging to the TNF family (BAFF) or anti-CD22 antibodies...
  10. ncbi request reprint Tides of inflammation: impact of biologics
    E William St Clair
    J Rheumatol Suppl 65:22-6. 2002
    ..The successful translation of this approach into the clinic has had a substantial effect on the care of patients with RA...
  11. ncbi request reprint Infliximab for the treatment of early rheumatoid arthritis
    Robin C Geletka
    Duke University Medical Centre, Division of Rheumatology and Immunology, Department of Medicine, Box 2918, Durham, NC 27710, USA
    Expert Opin Biol Ther 5:405-17. 2005
    ..The knowledge of the benefits of infliximab therapy for early RA affords groundwork for developing more effective treatment strategies that can minimise disease progression over the long term...
  12. ncbi request reprint Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies
    Barton F Haynes
    Duke University School of Medicine, Durham, NC 27710, USA
    Science 308:1906-8. 2005
    ..These results may have important implications for generating effective neutralizing antibody responses by using HIV-1 vaccines...
  13. ncbi request reprint Serum levels of soluble CD44 in primary Sjögren's syndrome
    M C Levesque
    Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
    J Rheumatol 27:1444-9. 2000
    ..To determine whether elevated soluble CD44 (sCD44) levels serve as a marker of inflammation and lymphoproliferation in primary Sjögren's syndrome (SS)...
  14. ncbi request reprint B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity
    Koichi Yanaba
    Department of Immunology, Duke University Medical Center, Durham, NC 27710, USA
    J Immunol 179:1369-80. 2007
    ....
  15. doi request reprint B-lymphocyte contributions to human autoimmune disease
    Koichi Yanaba
    Department of Immunology, Duke University Medical Center, Durham, NC 27710, USA
    Immunol Rev 223:284-99. 2008
    ....
  16. ncbi request reprint Smoking and use of hair treatments in relation to risk of developing systemic lupus erythematosus
    G S Cooper
    From the Epidemiology Branch, National Institute of Environmental Health Sciences, Durham, North Carolina 27709, USA
    J Rheumatol 28:2653-6. 2001
    ..To examine the association between smoking and hair treatments (dyes, permanents) and risk of developing systemic lupus erythematosus (SLE)...
  17. ncbi request reprint Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial
    E William St Clair
    Duke University Medical Center, Durham, North Carolina, USA
    Arthritis Rheum 50:3432-43. 2004
    ....
  18. ncbi request reprint Informed consent in a clinical trial of a novel treatment for rheumatoid arthritis
    Lisa G Criscione
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Arthritis Rheum 49:361-7. 2003
    ..To evaluate the informed consent process for a clinical trial of intravenous doxycycline for rheumatoid arthritis...
  19. ncbi request reprint Treatment of early rheumatoid arthritis
    Robin Geletka
    Division of Rheumatology, Department of Medicine, Duke University Medical Center, Duke South Hospital, Room 34229, Trent Drive, Durham, NC 27710, USA
    Best Pract Res Clin Rheumatol 17:791-809. 2003
    ..Controlled trials are needed in early disease to investigate these questions and to identify treatment strategies that can effectively induce sustained remission and prevent joint damage...
  20. ncbi request reprint New therapeutics in rheumatoid arthritis
    Christine Savage
    Duke University Medical Center, Durham, NC 27710, USA
    Rheum Dis Clin North Am 32:57-74, viii. 2006
    ..The approval of new drugs for this indication has expanded the number of therapeutic options that can potentially allow for tight control of the inflammatory process...
  21. ncbi request reprint Genetic polymorphisms in tumor necrosis factor (TNF)-alpha and TNF-beta in a population-based study of systemic lupus erythematosus: associations and interaction with the interleukin-1alpha-889 C/T polymorphism
    Christine G Parks
    National Institute of Environmental Health Sciences, Durham, NC, USA
    Hum Immunol 65:622-31. 2004
    ..0, p < 0.00001) for the combined "HLA-DR3, TNF-alpha -308A, IL-1alpha -889C/C" genotype. These findings provide evidence of cytokine gene epistasis in SLE susceptibility...
  22. ncbi request reprint Occupational exposure to crystalline silica and risk of systemic lupus erythematosus: a population-based, case-control study in the southeastern United States
    Christine G Parks
    Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Durham, North Carolina 27709, USA
    Arthritis Rheum 46:1840-50. 2002
    ..We undertook this population-based study to examine the association between occupational silica exposure and SLE in the southeastern US...
  23. pmc Novel targeted therapies for autoimmunity
    E William St Clair
    Department of Medicine, Duke University Medical Center, Box 3874 DUMC, Durham, NC 27710, USA
    Curr Opin Immunol 21:648-57. 2009
    ..In the future, treatment strategies may increasingly explore the use of drug combinations acting at multiple sites of aberrant immunoregulation to achieve disease quiescence and immune tolerance...
  24. ncbi request reprint CTLA-4 gene polymorphisms and systemic lupus erythematosus in a population-based study of whites and African-Americans in the southeastern United States
    C G Parks
    Epidemiology Branch, A3 05, NIEHS, NIH, DHHS, PO Box 12233, Durham, North Carolina 27709 12233, USA
    Lupus 13:784-91. 2004
    ..These findings suggest allelic variation in this region of CTLA4 is not a major independent risk factor for SLE, but may contribute to risk of disease in younger African-Americans or in the presence of certain immunogenetic markers...
  25. doi request reprint T cell large granular lymphocyte leukemia associated with rheumatoid arthritis and neutropenia
    Ankoor Shah
    Division of Rheumatology and Immunology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Clin Immunol 132:145-52. 2009
    ..Despite this difference, T-LGL and FS are often similar in their clinical and biological behavior. Both may respond to immunosuppressive therapy, and pursue a smoldering course typical of a chronic inflammatory disease...
  26. ncbi request reprint New reagents on the horizon for immune tolerance
    E William St Clair
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Annu Rev Med 58:329-46. 2007
    ....
  27. ncbi request reprint Risk factors for development of systemic lupus erythematosus: allergies, infections, and family history
    Glinda S Cooper
    Epidemiology Branch A3 05, National Institute of Environmental Health Sciences, PO Box 12233, Durham, NC 27709, USA
    J Clin Epidemiol 55:982-9. 2002
    ..3, 95% CI 1.2-8.6). Further research is needed to clarify whether medication allergies and specific infectious agents are involved in the etiology of SLE. Published by Elsevier Science Inc...
  28. ncbi request reprint Hormonal and reproductive risk factors for development of systemic lupus erythematosus: results of a population-based, case-control study
    Glinda S Cooper
    Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Durham, North Carolina 27709, USA
    Arthritis Rheum 46:1830-9. 2002
    ..In humans, 85% of lupus patients are women, which also suggests the importance of hormonal factors in disease pathogenesis. The purpose of this study was to examine hormonal and reproductive risk factors for lupus among women...
  29. ncbi request reprint N-acetyl transferase genotypes in relation to risk of developing systemic lupus erythematosus
    Glinda S Cooper
    Epidemiology Branch, National Institute of Environmental Health Sciences, Durham, North Carolina 27709, USA
    J Rheumatol 31:76-80. 2004
    ..To examine the association between N-acetyl transferase (NAT) genotype (NAT1 and NAT2) and risk of developing systemic lupus erythematosus (SLE)...
  30. ncbi request reprint Occupational risk factors for the development of systemic lupus erythematosus
    Glinda S Cooper
    Epidemiology Branch, National Institute of Environmental Health Sciences, Durham, North Carolina 27709, USA
    J Rheumatol 31:1928-33. 2004
    ..We examined the association between the risk of SLE and occupational exposures (mercury, solvents, and pesticides), specific jobs (ever worked in teaching, healthcare, and cosmetology), and working night or rotating shifts...
  31. ncbi request reprint Infliximab treatment maintains employability in patients with early rheumatoid arthritis
    Josef S Smolen
    Medical University of Vienna and Lainz Hospital, Vienna, Austria
    Arthritis Rheum 54:716-22. 2006
    ..To evaluate the impact of infliximab therapy on the employment status of patients with early rheumatoid arthritis (RA)...
  32. ncbi request reprint Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial
    Josef S Smolen
    Medical University of Vienna and Lainz Hospital, Vienna, Austria
    Arthritis Rheum 54:702-10. 2006
    ..To identify disease characteristics leading to progression of joint damage in patients with early rheumatoid arthritis (RA) treated with methotrexate (MTX) versus those treated with infliximab plus MTX...
  33. ncbi request reprint A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis
    John H Stone
    The Johns Hopkins Vasculitis Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, USA
    Arthritis Rheum 52:902-10. 2005
    ..To identify serum ion patterns that distinguish remission from active disease in patients with Wegener's granulomatosis (WG)...
  34. ncbi request reprint Association of anemia and physical disability among patients with rheumatoid arthritis
    Chenglong Han
    Centocor Research and Development Inc, 200 Great Valley Parkway, Malvern, PA 19355, USA
    J Rheumatol 34:2177-82. 2007
    ..To evaluate the relationship between hemoglobin concentration and physical disability in patients with rheumatoid arthritis (RA)...
  35. ncbi request reprint Sociodemographic associations with early disease damage in patients with systemic lupus erythematosus
    Glinda S Cooper
    US Environmental Protection Agency, Washington, DC 20460, USA
    Arthritis Rheum 57:993-9. 2007
    ..To examine the extent of organ damage among recently diagnosed patients with systemic lupus erythematosus (SLE), and to assess the association between sociodemographic variables and total damage and organ-specific damage scores...
  36. ncbi request reprint IgG and IgM anticardiolipin antibodies following treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis
    Sudha Visvanathan
    Centocor, Inc, Malvern, Pennsylvania 19355, USA
    Arthritis Rheum 54:2840-4. 2006
    ..To assess the occurrence of anticardiolipin antibodies (aCL) in patients with early rheumatoid arthritis (RA) receiving treatment with infliximab plus methotrexate (MTX) versus MTX alone...
  37. ncbi request reprint Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial
    John H Stone
    Johns Hopkins University, Baltimore, Maryland, USA
    Arthritis Rheum 54:1608-18. 2006
    ..This study was undertaken to further explore the potential association between anti-TNF therapy and the development of malignancy in these patients...
  38. ncbi request reprint New prospects for autoimmune disease therapy: B cells on deathwatch
    E William St Clair
    Arthritis Rheum 54:1-9. 2006
  39. ncbi request reprint Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET)
    Philip Seo
    Johns Hopkins University, Baltimore, Maryland
    Arthritis Rheum 52:2168-78. 2005
    ..To analyze damage occurring in patients with Wegener's granulomatosis (WG) enrolled in the WG Etanercept Trial (WGET) and to correlate that damage with disease activity, adverse events, and quality of life...
  40. ncbi request reprint CTLA4Ig: bridging the basic immunology with clinical application
    Jeffrey A Bluestone
    Diabetes Center, University of California, San Francisco, San Francisco, California 94143, USA
    Immunity 24:233-8. 2006
    ..Orencia is the first-in-class antagonist of CD28 costimulation. In this perspective, we discuss the science that led to CTLA4Ig development and the clinical challenges in bringing the drug from the bench to the bedside...
  41. doi request reprint Comparison of employability outcomes among patients with early or long-standing rheumatoid arthritis
    Chenglong Han
    Centocor Research and Development, Malvern, Pennsylvania 19355, USA
    Arthritis Rheum 59:510-4. 2008
    ....
  42. ncbi request reprint ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis
    Javier D Finkielman
    Thoracic Disease Research Unit, Division of Pulmonary and Critical Care Medicine, Mayo Clinic and Foundation, Rochester, Minn 55905, USA
    Am J Med 120:643.e9-14. 2007
    ..The objective of this study was to determine the frequency of ANCA in patients with active Wegener's granulomatosis and to assess the influence of disease severity on test results...
  43. ncbi request reprint Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis
    Javier D Finkielman
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Intern Med 147:611-9. 2007
    ..The utility of antineutrophil cytoplasmic antibody (ANCA) levels to guide the management of patients with Wegener granulomatosis remains controversial...
  44. ncbi request reprint Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases
    R John Looney
    Autoimmunity Centers of Excellence ACE Immunocompetency Committee, Rochester, USA
    Clin Immunol 123:235-43. 2007
    ..Banking genetic material to allow genotyping should be considered particularly if a central repository for samples from different trials can be established...
  45. ncbi request reprint Antiendothelial cell antibodies in patients with Wegener's granulomatosis: prevalence and correlation with disease activity and manifestations
    Jodi K Sebastian
    Boston University, Boston, Massachusetts 02118, USA
    J Rheumatol 34:1027-31. 2007
    ..We examined a large, well-characterized cohort of patients with WG and active disease for the presence of AECA...
  46. ncbi request reprint Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study
    Peter A Merkel
    Boston University School of Medicine, Vasculitis Center, E 5, 715 Albany Street, Boston, MA 02118, USA
    Ann Intern Med 142:620-6. 2005
    ..Venous thrombotic events (VTEs) have been observed in Wegener granulomatosis, but the incidence rate is not known...
  47. ncbi request reprint Herpes zoster in immunocompromised patients: incidence, timing, and risk factors
    Peter K Wung
    Johns Hopkins University School of Medicine, Johns Hopkins University, Baltimore, MD, USA
    Am J Med 118:1416. 2005
    ..To evaluate the risk factors for herpes zoster as well as the incidence and timing of this complication in patients who were treated with immunosuppression because of active Wegener's granulomatosis...

Research Grants6

  1. Abatacept Vs TNF Blockade in Early Rheumatoid Arthritis
    EUGENE ST CLAIR; Fiscal Year: 2007
    ..The proposed clinical trial will compare the remission-inducing capabilities of two novel therapies for early RA, and search for biomarkers that predict treatment response. ..
  2. NOVEL THERAPEUTIC TARGETS IN RHEUMATOID ARTHRITIS
    EUGENE ST CLAIR; Fiscal Year: 2003
    ..St.Clair with outstanding clinical research opportunities and educational experiences for his trainees. ..
  3. Clinical Research Component
    EUGENE ST CLAIR; Fiscal Year: 2003
    ..abstract_text> ..
  4. Modulation of B Cell Responses in Autoimmunity
    EUGENE ST CLAIR; Fiscal Year: 2007
    ..Overall, the Proposed Center will efficiently bridge basic and clinical investigations and should produce new insights into the immunotherapy of autoimmune disease. ..
  5. ACR Basic Research Conference
    EUGENE ST CLAIR; Fiscal Year: 2007
    ..Salmon, is the current COR Chair. The purpose of this is to facilitate the yearly organization of the conference under the auspices of the standing committee charged with this purpose by the ACR Board of Directors. ..